METADATE CD

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
METADATE CD
Generic name
METHYLPHENIDATE HYDROCHLORIDE
Manufacturer
Lannett Company, LLC
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
29f06562-6b6a-4ca6-b62e-d08a45fb3dd4
SPL ID
67f59673-53d1-4e48-9c9a-fb8bed2eab3a
Version
4
Effective date
2026-10-21
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:35:09
Harmonized routes table
Harmonized routes
ORAL

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION METADATE CD has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including METADATE CD, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with a higher dosage or unapproved methods of administration, such as snorting or injection. Before prescribing METADATE CD, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of METADATE CD, and proper disposal of any unused drug. Throughout METADATE CD treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE, MISUSE, AND ADDICTION See full prescribing information for complete boxed warning. METADATE CD has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including METADATE CD, can result in overdose and death ( 5.1 , 9.2 , 10 ): Before prescribing METADATE CD, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of METADATE CD, and proper disposal of any unused drug. Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Risks to Patients with Serious Cardiac Disease : Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. ( 5.2 ) Increased Blood Pressure and Heart Rate : Monitor blood pressure and heart rate. ( 5.3 ) Psychiatric Adverse Reactions : If new psychotic or manic symptoms occur, consider discontinuing METADATE CD. ( 5.4 ) Priapism : If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention. ( 5.5 ) Peripheral Vasculopathy, including Raynaud’s Phenomenon : Carefully assess for digital changes during METADATE CD treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy. ( 5.6 ) Long-Term Suppression of Growth in Pediatric Patients : Closely monitor growth (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their METADATE CD treatment interrupted. ( 5.7 ) Acute Angle Closure Glaucoma : METADATE CD-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist. ( 5.8 ) Increased Intraocular Pressure (IOP) and Glaucoma : Prescribe METADATE CD to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor patients with a history of increased IOP or open angle glaucoma. ( 5.9 ) Motor and Verbal Tics, and Worsening of Tourette Syndrome : Regularly monitor patients for the emergence or worsening of tics or Tourette syndrome. Discontinue METADATE CD if clinically appropriate. ( 5.10 ) 5.1 Abuse, Misuse, and Addiction METADATE CD has a high potential for abuse and misuse. The use of METADATE CD exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including METADATE CD, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with a higher dosage or unapproved methods of administration, such as snorting or injection. Before prescribing METADATE CD, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients and/or their caregivers to store METADATE CD in a safe place, preferably locked, and instruct patients and/or their caregivers to not give METADATE CD to anyone else. Throughout METADATE CD treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction. 5.2 Risks to Patients with Serious Cardiac Disease Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended dosage. Prior to treating patients with METADATE CD, assess for the presence of cardiac disease (e.g., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam). Avoid METADATE CD use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac problems. 5.3 Increased Blood Pressure and Heart Rate CNS stimulants cause an increase in blood pressure (mean increase approximately 2 to 4 mmHg) and heart rate (mean increase approximately 3 to 6 bpm). Some patients may have larger increases. Monitor all METADATE CD treated patients for hypertension and tachycardia. 5.4 Psychiatric Adverse Reactions Exacerbation of Pre-Existing Psychosis in Patients with a Psychotic Disorder CNS stimulants, including METADATE CD, may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Induction of a Manic Episode in Patients with Bipolar Disorder CNS stimulants, including METADATE CD, may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating METADATE CD treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression). New Psychotic or Manic Symptoms in Patients without a History of a Bipolar or Psychotic Disorder CNS stimulants, including METADATE CD, at the recommended dosages, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNC stimulant-treated patients, compared to 0% of placebo-treated patients. If such symptoms occur, consider discontinuing METADATE CD. 5.5 Priapism Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate use in both adult and pediatric male patients. Although priapism was not reported with methylphenidate initiation, it developed after some time on methylphenidate, often subsequent to an increase in dosage. Priapism also occurred during methylphenidate withdrawal (drug holidays or during discontinuation). METADATE CD-treated patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention. 5.6 Peripheral Vasculopathy, Including Raynaud’s Phenomenon CNS stimulants, including METADATE CD, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms of these cases of peripheral vasculopathy were usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports and at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction in or discontinuation of the CNS stimulant. Carefully assess for digital changes during METADATE CD treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for METADATE CD-treated patients who develop signs of symptoms of peripheral vasculopathy. 5.7 Long-Term Suppression of Growth in Pediatric Patients CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Careful follow-up of weight and height in pediatric patients ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated pediatric patients over 36 months (to the ages of 10 to 13 years), suggests that pediatric patients who received methylphenidate treatment for 7 days per week throughout the year had a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this development period. METADATE CD is not approved for use and is not recommended in pediatric patients below 6 years of age because of a higher incidence of adverse reactions including weight loss [see Use in Specific Populations ( 8.4 )] . Closely monitor growth (weight and height) in METADATE CD-treated pediatric patients. Pediatric patients who are not growing or gaining height or weight as expected may need to have their METADATE CD treatment interrupted. 5.8 Acute Angle Closure Glaucoma There have been reports of angle closure glaucoma associated with methylphenidate treatment. Although the mechanism is not clear, METADATE CD-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist. 5.9 Increased Intraocular Pressure and Glaucoma There have been reports of an elevation of intraocular pressure (IOP) associated with methylphenidate treatment [see Adverse Reactions ( 6.2 )] . Prescribe METADATE CD to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor METADATE CD-treated patients with a history of abnormally increased IOP or open angle glaucoma. 5.10 Motor and Verbal Tics, and Worsening of Tourette Syndrome CNS stimulants, including methylphenidate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette syndrome has also been reported [see Adverse Reactions ( 6.2 )] . Before initiating METADATE CD, assess the family history for tics or Tourette syndrome and clinically evaluate patients for tics or Tourette syndrome. Regularly monitor METADATE CD-treated patients for the emergence or worsening of tics or Tourette syndrome, and discontinue METADATE CD if clinically appropriate.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling: Abuse, Misuse, and Addiction [see Warnings and Precautions ( 5.1 ), Drug Abuse and Dependence ( 9.2 , 9.3 )] Risks to Patients with Serious Cardiac Disease [see Warnings and Precautions ( 5.2 )] Increased Blood Pressure and Heart Rate [see Warnings and Precautions ( 5.3 )] Psychiatric Adverse Reactions [see Warnings and Precautions ( 5.4 )] Priapism [see Warnings and Precautions ( 5.5 )] Peripheral Vasculopathy, including Raynaud’s Phenomenon [see Warnings and Precautions ( 5.6 )] Long-Term Suppression of Growth in Pediatric Patients [see Warnings and Precautions ( 5.7 )] Acute Angle Closure Glaucoma [see Warnings and Precautions ( 5.8 )] Increased Intraocular Pressure and Glaucoma [see Warnings and Precautions ( 5.9 )] Motor and Verbal Tics, and Worsening of Tourette Syndrome [see Warnings and Precautions ( 5.10 )] The most common adverse reactions (≥ 5% in METADATE-CD-treated patients and greater than in placebo-treated patients) were headache, anorexia, abdominal pain, and insomnia ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc. at 1-844-834-0530 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety database is based on three clinical studies of METADATE CD (i.e., Studies 1, 2, and 3) that included 188 METADATE CD-treated pediatric patients 6 years of age and older with ADHD. Pediatric patients received METADATE CD 20 mg, 40 mg, and/or 60 mg once daily: Study 1 was a 3-week placebo-controlled clinical study that included 314 pediatric patients (ages 6 to 15 years; METADATE CD n=155) Study 2 was a placebo-controlled, crossover clinical study that included 25 pediatric patients (ages 7 to 12 years); and Study 3 was an uncontrolled clinical study that included 8 pediatric patients (ages 6 to 10 years). Adverse Reactions Leading to Discontinuation of Treatment In Study 1, 1% (2/155) METADATE CD-treated patients and no placebo-treated patients discontinued due to an adverse reaction. One METADATE CD-treated patient discontinued due to rash and pruritus; and the other METADATE CD-treated patient discontinued due headache, abdominal pain, and dizziness. Most Common Adverse Reactions The most common adverse reactions that occurred in 5% or more of METADATE CD-treated and at least twice as great in the METADATE CD-treated patients compared to the placebo-treated patients in a pool of Studies 1, 2 and 3 in pediatric patients 6 to 15 years of age were anorexia and insomnia. Adverse reactions that occurred in ≥5% of METADATE CD-treated patients with a greater incidence in METADATE CD-treated patients than placebo-treated patients in pooled Studies, 1, 2, and 3 are presented in Table 2: Table 2: Adverse Reactions 1 in Pediatric Patients Ages 6 to 15 Years with ADHD in Pooled Three to Four Week Trials (Studies 1, 2, and 3) METADATE CD (n=188) Placebo (n=190) Headache 12% 8% Anorexia 9% 2% Abdominal Pain 7% 4% Insomnia 5% 2% 1 Adverse reactions that occurred in ≥5% of METADATE CD-treated patients with a greater incidence in METADATE CD-treated patients than placebo-treated patients 6.2 Postmarketing Experience The following adverse reactions have been identified during postmarketing use of METADATE CD and other methylphenidate products. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse Reactions with METADATE CD Blood and the lymphatic system disorders: thrombocytopenia Cardiac disorders: cardiac arrest, sudden death Immune system disorders: angioedema Musculoskeletal and connective tissue disorders: rhabdomyolysis Psychiatric disorders: abnormal behavior, aggression, anxiety, irritability, obsessive-compulsive disorder, suicidal behavior (including completed suicide), libido changes, serotonin syndrome in combination with serotonergic drugs Nervous System Disorder : migraine, reversible ischemic neurological deficit, bruxism Skin and subcutaneous tissue disorders: fixed drug eruption Vascular disorders: peripheral coldness, Raynaud’s phenomenon Adverse Reactions with Other Methylphenidate Products Blood and the lymphatic system disorders: leukopenia, anemia, pancytopenia Cardiac disorders: palpitations; increased blood pressure, tachycardia, angina pectoris, cardiac arrhythmia, myocardial infarction, bradycardia, extrasystole Eye disorders: blurred vision, difficulties in visual accommodation, diplopia, increased intraocular pressure, mydriasis Gastrointestinal disorders : nausea, abdominal pain, dry mouth, vomiting, dyspepsia, diarrhea, constipation General Disorders: fatigue, hyperpyrexia Hepatobiliary disorders: abnormal liver function, ranging from transaminase elevation to severe hepatic injury Immune system disorders : hypersensitivity, including anaphylaxis, auricular swelling, bullous conditions, eruptions, exanthemas Infections and infestations: nasopharyngitis Metabolism and nutrition disorders: decreased appetite, reduced weight gain and suppression of growth during prolonged use in pediatric patients Musculoskeletal and connective tissue disorders: arthralgia, muscle cramps, myalgia, muscle twitching Nervous System Disorder: nervousness, dizziness, headache, dyskinesia, including choreoatheetoid movements, drowsiness, tremor, convulsions, cerebrovascular disorders (including vasculitis, cerebral hemorrhages and cerebrovascular accidents), serotonin syndrome in combination with serotonergic drugs, motor and verbal tics Psychiatric disorders: depressed mood, restlessness, agitation, psychosis (sometimes with visual and tactile hallucinations), affect liability, mania, disorientation Renal and urinary disorders: hematuria Reproductive system and breast disorders: gynecomastia Respiratory, thoracic and mediastinal disorders: pharyngolaryngeal pain, dyspnea, cough Skin and subcutaneous tissue disorders: scalp hair loss, hyperhidrosis, angioneurotic edema, erythema, exfoliative dermatitis, thrombocytopenic purpura, urticaria, erythema multiforme rash Urogenital disorders: priapism Vascular disorders: isolated cases of cerebral arteritis and/or occlusion

adverse reactions table

<table> <caption>Table 2: Adverse Reactions<sup>1</sup> in Pediatric Patients Ages 6 to 15 Years with ADHD in Pooled Three to Four Week Trials (Studies 1, 2, and 3)</caption> <col/> <col/> <col/> <tbody> <tr> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">METADATE CD <content styleCode="underline">(n=188)</content> </content> </paragraph> </td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> <paragraph> <content styleCode="bold">Placebo <content styleCode="underline">(n=190)</content> </content> </paragraph> </td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> Headache</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 12%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8%</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> Anorexia</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 9%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2%</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> Abdominal Pain</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 7%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">4%</td> </tr> <tr> <td styleCode=" Botrule Toprule Lrule Rrule"> Insomnia</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">5%</td> <td align="center" styleCode=" Botrule Toprule Lrule Rrule">2%</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.